Put Options

8 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$0.36 - $0.61 $18,144 - $30,744
50,400 Added 69.42%
123,000 $47,000
Q1 2024

May 15, 2024

SELL
$0.4 - $0.91 $68,400 - $155,610
-171,000 Reduced 70.2%
72,600 $38,000
Q4 2023

Feb 14, 2024

BUY
$0.71 - $0.97 $90,170 - $123,190
127,000 Added 108.92%
243,600 $221,000
Q3 2023

Nov 14, 2023

SELL
$0.96 - $2.01 $12,960 - $27,134
-13,500 Reduced 10.38%
116,600 $114,000
Q2 2023

Aug 14, 2023

SELL
$1.59 - $2.29 $16,377 - $23,587
-10,300 Reduced 7.34%
130,100 $227,000
Q1 2023

May 15, 2023

SELL
$2.05 - $2.87 $119,719 - $167,608
-58,400 Reduced 29.38%
140,400 $320,000
Q4 2022

Feb 14, 2023

BUY
$2.06 - $3.47 $62,212 - $104,794
30,200 Added 17.91%
198,800 $429,000
Q3 2022

Nov 14, 2022

SELL
$2.6 - $5.12 $14,300 - $28,160
-5,500 Reduced 3.16%
168,600 $482,000

Others Institutions Holding ME

About 23andMe Holding Co.


  • Ticker ME
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 259,768,000
  • Market Cap $80.5M
  • Description
  • 23andMe Holding Co. operates as a consumer genetics testing company. It operates through two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of pa...
More about ME
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.